ASH Clinical Practice Guidelines on Dosing and Monitoring of Hydroxyurea for Sickle Cell Disease
In 2024, in response to long-standing member interest, ASH approved a plan to develop clinical practice guidelines on Dosing and Monitoring of Hydroxyurea for Sickle Cell Disease. Like other ASH guidelines, these new guidelines will be developed using methods that meet the highest standards for rigor and trust. The development process will include formation of an expert panel, systematic reviews of available evidence, structured recommendations, and public review.
Download ASH’s COI policy to learn more about management of conflicts of interest in the development of Clinical Practice Guidelines by the American Society of Hematology.
ASH continues its long-standing commitment to supporting scientists and clinicians from backgrounds underrepresented in medicine and embraces diverse voices across the patient and health care communities. Learn more about ASH’s commitment to diversity, equity and inclusion in health care.